The best Drug Discovery newsletters

Long-form essays examining the scientific claims and limits of biological research, especially organoids in drug discovery, disease modeling, and Alzheimer's research. Readers get critical, detailed analysis of where lab models succeed, fail, and get overhyped, plus updates from the author's work on AI and health.

Official blog of the Open Targets platform, covering data releases, new genomic datasets and the research behind them. Readers get detailed release notes and behind-the-scenes stories on target identification for drug discovery.

A personal-essay-driven newsletter on data, companies and ideas at the frontier of biology, covering topics like AI in drug discovery, the economics of pharma R&D and founder stories. Readers get long-form analysis of the biotech landscape, investments and historical context of life sciences.

A weekly newsletter tracking AI and computational drug discovery, covering deals, startups, funding rounds and research papers in biopharma. Each issue pairs a main analytical essay with a roundup of recent industry news.

Kaleidoscope, a biotech R&D company, publishes essays on the economics and operations of drug development, covering talent motivation, the shift of early trials to China, and inefficiencies in lab operations. Readers get founder-level perspective on the business and strategy of biopharma, with a focus on where AI can practically help.

MoleculeInsight is a blog-style newsletter of essays on modern drug discovery, explaining concepts such as plasma protein binding, molecular interactions, hit discovery and ADME. It also covers the newsletter's educational product MedChemify and wider links between AI, 3D modelling and molecular science.

A daily brief covering AI agents in biomedical and drug discovery, pairing short news items with 'why it matters' commentary on each. The sample issues cover OpenAI's acquisition of a drug-development agent startup, lab-designed binders and benchmark studies of agent reliability.

A corporate blog from Genetic Leap, a company using AI and computational platforms for genetically-defined drug target selection and RNA-targeted therapeutics. Posts cover company news, conference appearances and technical perspectives on experimental validation of AI-driven predictions.

A weekly automated digest that compiles and briefly summarises recent peer-reviewed papers at the intersection of machine learning, computational biology and drug discovery. Readers get a quick scan of notable protein design, single-cell and genomics studies, each with a one-line description and publication details.